Please use this identifier to cite or link to this item:
Title: Nitric oxide modulation of the basal ganglia circuitry : therapeutic implication for Parkinson’s disease and other motor disorders
Authors: Pierucci, Massimo
Galati, Salvatore
Valentino, Mario
Matteo, Vincenzo di
Benigno, Arcangelo
Pitruzzella, Alessandro
Muscat, Richard
Di Giovanni, Giuseppe
Keywords: Nitric oxide
Basal ganglia
Parkinson’s disease
Movement disorders
Issue Date: 2011
Publisher: Bentham Science Publishers Ltd.
Citation: M. Pierucci, S.Galati, M. Valentino, V. Di Matteo, A. Benigno, A. Pitruzzella, R..., G. Di Giovanni. (2011). Nitric oxide modulation of the basal ganglia circuitry : therapeutic implication for Parkinson’s disease and other motor disorders. CNS & Neurological Disorders - Drug Targets, 10(7), 777-791.
Abstract: Several recent studies have emphasized a crucial role for the nitrergic system in movement control and the pathophysiology of the basal ganglia (BG). These observations are supported by anatomical evidence demonstrating the presence of nitric oxide synthase (NOS) in all the basal ganglia nuclei. In fact, nitrergic terminals have been reported to make synaptic contacts with both substantia nigra dopamine-containing neurons and their terminal areas such as the striatum, the globus pallidus and the subthalamus. These brain areas contain a high expression of nitric oxide (NO)-producing neurons, with the striatum having the greatest number, together with important NO afferent input. In this paper, the distribution of NO in the BG nuclei will be described. Furthermore, evidence demonstrating the nitrergic control of BG activity will be reviewed. The new avenues that the increasing knowledge of NO in motor control has opened for exploring the pathophysiology and pharmacology of Parkinson's disease and other movement disorders will be discussed. For example, inhibition of striatal NO/guanosine monophosphate signal pathway by phosphodiesterases seems to be effective in levodopa-induced dyskinesia. However, the results of experimental studies have to be interpreted with caution given the complexities of nitrergic signalling and the limitations of animal models. Nevertheless, the NO system represents a promising pharmacological intervention for treating Parkinson's disease and related disorders.
Appears in Collections:Scholarly Works - FacM&SPB

Files in This Item:
File Description SizeFormat 
Nitric Oxide Modulation of the Basal Ganglia Circuitry. Therapeutic.pdf1.9 MBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.